Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 4
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Nierkens, Stefan and Janssen, Edith M. 2011. Harnessing Dendritic Cells for Tumor Antigen Presentation. Cancers, Vol. 3, Issue. 4, p. 2195.

    Cancemi, Patrizia Albanese, Nadia Ninfa Cara, Gianluca Di Marabeti, Maria Rita Costantini, Francesca Minafra, Salvatore and Pucci-Minafra, Ida 2010. Multiple Changes Induced by Fibroblasts on Breast Cancer Cells. Connective Tissue Research, Vol. 51, Issue. 2, p. 88.

    Joyce, Johanna A. and Pollard, Jeffrey W. 2009. Microenvironmental regulation of metastasis. Nature Reviews Cancer, Vol. 9, Issue. 4, p. 239.

    Schiffelers, Raymond M. and Storm, Gert 2008. Liposomal nanomedicines as anticancer therapeutics: Beyond targeting tumor cells. International Journal of Pharmaceutics, Vol. 364, Issue. 2, p. 258.


Tumour–host interactions: implications for developing anti-cancer therapies

  • Bedrick B. Gadea (a1) and Johanna A. Joyce (a1)
  • DOI:
  • Published online: 01 December 2006

Cancers are a complex set of proliferative diseases that arise in most cases through multi-step pathways involving an accumulation of genetic and epigenetic changes. These steps include inactivation of tumour suppressor genes and activation of oncogenes. However, in addition to genetic mutations in the tumour cells themselves, the local host environment can act as a critical modulator of cancer progression, having either tumour-suppressive or tumour-promoting effects depending on the stage and site of cancer development. Because stromal cells can have these opposing functions during cancer development and progression, a recurring theme throughout this review will be that of balance: maintaining the normal functions of these co-opted cells, yet selectively inhibiting their pro-tumourigenic functions. To achieve this equilibrium, we need to understand the molecular mechanisms by which normal cells become modified by cancer cells before we can hope to target these functions selectively. Here, we will discuss recent efforts to address these key challenges and offer perspectives on the translation of discoveries made in model systems to the clinic.

Corresponding author
Corresponding author: Johanna A. Joyce, Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, Box 372, New York, NY 10021, USA. Tel: +1 646 888 2048; Fax: +1 646 422 0231; E-mail:
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *